TCR2 Therapeutics to Present New Preclinical Data at the American Association for Cancer Research (AACR) 2018 Annual Meeting
CAMBRIDGE, Mass., April 12, 2018 /PRNewswire/ -- TCR2 Therapeutics Inc., an immuno-oncology company pioneering a novel class of T cell receptor (TCR)-based cellular therapies for solid tumors and blood cancers, announced today that new preclinical data on its TRuCtm platform and its lead solid tumor program TC-210 will be presented at the American Association for Cancer Research (AACR) 2018 Annual Meeting to be held April 14-18, 2018 in Chicago, IL.
The poster presentations will discuss rationales and mechanisms for the company's HLA-independent TRuCtm-T cells and provide additional updates for TC-210, the company's lead program targeting mesothelin-positive solid tumors. TC-210 is advancing into the clinic later this year for solid tumor indications including ovarian, mesothelioma, cholangiocarcinoma, pancreatic and lung cancers. Abstracts are available on the AACR conference website at http://www.aacr.org.
Abstract #3584
Title: Characterization of a novel class of engineered (TCR) fusion constructs (TRuCtms) aimed to treat solid tumors
Date & Time: Tuesday, April 17, 20188:00 AM - 12:00 PM CDT
Location: McCormick Place South, Exhibit Hall A, Poster Section 24
Abstract #3589
Title: Preclinical evaluation of mesothelin-specific T cell receptor (TCR) fusion constructs (TRuCtms) utilizing the signaling power of the complete TCR complex: A new opportunity for solid tumor therapy
Date & Time: Tuesday, April 17, 20188:00 AM - 12:00 PM CDT
Location: McCormick Place South, Exhibit Hall A, Poster Section 24
About TCR2 Therapeutics TCR2 Therapeutics is an immuno-oncology company that has pioneered a novel class of T cell therapies for solid tumors and blood cancers that utilize the full signaling power of complete T cell receptors (TCR) without the need for HLA-matching. TCR2's proprietary multi-format TRuCtm platform reprograms the natural TCR complex to elicit rapid killing of cancer cells with long persistence and low cytokine release. The company has demonstrated superior activity against several tumor targets in preclinical models compared to CAR T cells and will advance its lead solid tumor program TC-210 targeting mesothelin into the clinic in 2018. TCR2 was founded in 2015 by renowned German immunologist Dr. Patrick Baeuerle and now led by a world-class team of immunotherapy experts and entrepreneurs in the heart of Kendall Square in Cambridge, MA. For more information, please visit www.tcr2.com.
Neuroscientists have established in recent decades the idea that some of each day's experiences are converted by the brain into permanent memories during sleep the same night. Now, a new study proposes a mechanism that determines which memories are...
While traditional diaper rash creams are thick, sticky, and messy, Taro's new bébé Bottoms Diaper Rash Crème Spray allows for easy, one-handed application of a gentle spray formula that is touch-free with no rubbing needed. The light spray, which...
An expert panel has published the first performance measures to identify remission and evaluate the effectiveness of lifestyle medicine treatments, which will allow more objective comparisons between lifestyle behavior interventions and other...
BRIJ Medical proudly welcomes three distinguished industry leaders to its Board of Directors: John Grotting, Bob Zollars, and Jim Hinrichs. Leveraging their extensive experience and insights, they will steer the company's strategic vision and drive...
Everyone deserves to succeed. But today, for too many Canadians, your hard work isn't paying off like it did for previous generations. Your paycheque doesn't go as far as costs go up, and saving enough to go after your dreams seems harder and harder....
With sadness, AAD announced today that its influential board member and investor James Herbert has died following a lengthy battle with cancer. He was 83....